GNTI-932, an allogeneic engineered Treg product for the treatment of Inflammatory Bowel Disease
GNTI-932
Allogeneic EngTreg
- Designed to home to the gut and restore immune tolerance
- Inflammatory Bowel Disease
- Development candidate declared; IND as early as 2027
GNTI-932 is an allogeneic, off-the-shelf engineered T regulatory cell (EngTregs™) therapy designed to restore immune balance in patients with Inflammatory Bowel Disease (IBD). Built on GentiBio’s proprietary EngTreg platform, GNTI-932 addresses key challenges in Treg therapy development, including phenotypic instability, limited IL-2 availability, and lack of tissue specificity.
GNTI-932 incorporates a gut-specific chimeric antigen receptor (CAR) to enable precise localization and expansion of EngTregs at sites of intestinal inflammation. This targeted approach enhances immunosuppressive activity where it is needed most. The product also leverages GentiBio’s hypoimmune engineering technology to evade immune rejection, supporting repeat dosing and reducing cost of goods (CoG) to levels comparable with biologics.
About Inflammatory Bowel Disease
Inflammatory Bowel Disease (IBD) is a chronic autoimmune condition characterized by persistent inflammation of the gastrointestinal tract. The two primary forms of IBD are Crohn’s Disease (CD), which can affect any part of the digestive tract and often involves patchy, transmural inflammation, and Ulcerative Colitis (UC), which is confined to the colon and rectum and typically presents with continuous mucosal inflammation.
Both CD and UC result from a dysregulated immune response to gut microbiota in genetically susceptible individuals, leading to progressive tissue damage, debilitating symptoms, and impaired quality of life. Current treatment options, including biologics, often fail to achieve durable remission and may carry significant side effects.
As an off-the-shelf, single-dose, highly specific therapy with the potential for minimal side effects, GNTI-932 offers a transformative approach to treating IBD.